Delayed-type (Type IV) hypersensitivity is driven by a T cell–mediated response, specifically that the T helper 1 (Th1) subset steers this process. Th1 cells differentiate and release cytokines like IFN-γ that activate macrophages, leading to the macrophage-dominated inflammation seen in DTH reactions. The response takes time to develop because it requires antigen presentation, T cell activation, and macrophage activation, typically peaking after 24–72 hours. This is why DTH reactions occur later after exposure, as in the tuberculin skin test or contact dermatitis. Other helper T cell subsets have different roles: Th2 cells promote antibody-mediated responses and allergic reactions (not the classic DTH), Th17 cells recruit neutrophils and are involved in certain mucosal defenses and autoimmune processes, and regulatory T cells suppress immune responses. Therefore, Th1 cells are the best fit for delayed-type hypersensitivity.

This tests a sensitive serologic method used to detect specific antibodies or antigens in serum, typically employed as a screening test with a confirmatory step. In ELISA, the target antigen or antibody is captured on a solid surface, and an enzyme-labeled secondary antibody produces a color change that reflects the amount of target present. Its high sensitivity makes it ideal for screening large numbers of samples for infections or immune markers. Because ELISA can yield false positives, a more specific test is used to confirm positive results. Western blot fits this role well: it separates viral or bacterial proteins by electrophoresis, transfers them to a membrane, and uses patient antibodies to reveal which specific proteins are recognized. The pattern of bands provides higher specificity, helping distinguish true infections from cross-reactivity or nonspecific binding. Other methods like immunofluorescence can detect antibodies but are less practical for high-throughput screening, and agglutination tests are less sensitive. Western blot is typically reserved as a confirmatory step rather than a primary screening test.

FOXP3 is the master regulator that drives regulatory T cell development and their suppressive function. Regulatory T cells, which help maintain immune tolerance, express CD4, CD25, and FOXP3. FOXP3 controls a transcriptional program that enables these cells to dampen immune responses, partly by promoting molecules like CTLA-4, IL-10, and TGF-β. When FOXP3 is absent or defective, regulatory T cells fail to develop properly or lose their suppressive activity, leading to severe autoimmunity such as IPEX syndrome. Other transcription factors—GATA3 for Th2, T-bet for Th1, and RORγt for Th17—define other helper T cell lineages and are not essential for regulatory T cell development. Thus, FOXP3 is the essential transcription factor for regulatory T cell development.

This question targets IgE-mediated immediate hypersensitivity. In this type, exposure to an allergen first leads to IgE production by B cells under the influence of Th2 cytokines (like IL-4). The produced IgE binds to FcεRI receptors on mast cells and basophils, sensitizing them. Upon subsequent exposure, the allergen cross-links the bound IgE, triggering rapid degranulation of these cells and release of mediators such as histamine, leukotrienes, and prostaglandins. These mediators cause immediate effects: vasodilation and increased vascular permeability (edema), smooth muscle contraction (bronchoconstriction), and mucous secretion, producing symptoms like hives, runny nose, wheezing, or, in severe cases, anaphylaxis. The hallmark is that this reaction is IgE-dependent and occurs within minutes of exposure. In contrast, other hypersensitivities involve different mechanisms: antibody-mediated cytotoxic reactions use IgG or IgM against cell surfaces or tissues; immune complex–mediated reactions involve deposition of antigen–antibody complexes; and T cell–mediated delayed-type hypersensitivity relies on sensitized T cells rather than antibodies and takes longer to manifest.